Tengion Inc (TNGNQ)
Tengion Inc. was a biotechnology company focused on regenerative medicine and the development of neo-organs and related products designed to repair, regenerate, or replace damaged tissue and organs. Its pipeline included Neo-Kidney Augment, intended to help delay dialysis in patients with advanced chronic kidney disease, and Neo-Urinary Conduit, which was being studied in a Phase I clinical trial for use after bladder removal surgery. The company also had a licensing agreement with Children’s Medical Center Corporation covering certain tissue engineering patent and intellectual property rights. Founded in 2003 and headquartered in Winston-Salem, North Carolina, Tengion later filed for Chapter 7 liquidation in December 2014.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-TNGN.Q
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0.0%
|
—
|
—
|
—
|
—
|
0.04 K
|
—
|
—
|
—
|
—
|
—
|
—
|
